{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06282575",
            "orgStudyIdInfo": {
                "id": "JZP598-302"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508219-21-00",
                    "type": "OTHER",
                    "domain": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Jazz Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
            "officialTitle": "An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "efficacy-and-safety-of-zanidatamab-with-standard-of-care-therapy-against-standard-of-care-therapy-for-advanced-positive-biliary-tract-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-21",
            "studyFirstSubmitQcDate": "2024-02-21",
            "studyFirstPostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Jazz Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Biliary Tract Cancer",
                "HER2 Gene Mutation"
            ],
            "keywords": [
                "JZP598",
                "ZW25",
                "HER-2 positive BIliary Tract cancer",
                "Gallbladder Cancer",
                "Intrahepatic Cholangiocarcinoma (ICC)",
                "Extrahepatic Cholangiocarcinoma (ECC)",
                "Zanidatamab"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 286,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Zanidatamab with Standard-of-care Therapy Arm",
                    "type": "EXPERIMENTAL",
                    "description": "Zanidatamab plus standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.",
                    "interventionNames": [
                        "Drug: Zanidatamab",
                        "Drug: Cisplatin",
                        "Drug: Gemcitabine",
                        "Drug: Pembrolizumab",
                        "Drug: Durvalumab"
                    ]
                },
                {
                    "label": "Standard-of-care Therapy Arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.",
                    "interventionNames": [
                        "Drug: Cisplatin",
                        "Drug: Gemcitabine",
                        "Drug: Pembrolizumab",
                        "Drug: Durvalumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Zanidatamab",
                    "description": "Administered intravenously (IV)",
                    "armGroupLabels": [
                        "Zanidatamab with Standard-of-care Therapy Arm"
                    ],
                    "otherNames": [
                        "ZW25",
                        "JZP598"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "Administered intravenously (IV)",
                    "armGroupLabels": [
                        "Standard-of-care Therapy Arm",
                        "Zanidatamab with Standard-of-care Therapy Arm"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "Administered intravenously (IV)",
                    "armGroupLabels": [
                        "Standard-of-care Therapy Arm",
                        "Zanidatamab with Standard-of-care Therapy Arm"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Administered intravenously (IV)",
                    "armGroupLabels": [
                        "Standard-of-care Therapy Arm",
                        "Zanidatamab with Standard-of-care Therapy Arm"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Durvalumab",
                    "description": "Administered intravenously (IV)",
                    "armGroupLabels": [
                        "Standard-of-care Therapy Arm",
                        "Zanidatamab with Standard-of-care Therapy Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors",
                    "description": "PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause.",
                    "timeFrame": "Up to 52 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall survival (OS) in participants with IHC 3+ tumors",
                    "description": "OS is defined as the time from randomization to death, due to any cause.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Progression Free Survival for all participants",
                    "description": "PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "OS for all participants",
                    "description": "OS is defined as the time from randomization to death, due to any cause.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Number of participants achieving Confirmed objective response rate (cORR)",
                    "description": "Confirmed objective response rate is defined as achieving a confirmed best overall response of Complete Response (CR) or Partial Response (PR)",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "Duration of response is defined as the time from the first objective response (CR or PR) to documented Progressive Disease (PD) or death, from any cause.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Number of Patients reporting Treatment-Emergent Adverse Events (TEAE)",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Maximum serum concentration of Zanidatamab",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Number of participants who develop Anti-drug antibodies (ADAs) to Zanidatamab",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "Time to definitive deterioration (TDD) for participants with IHC 3+ tumors in patient-reported Physical Functioning (PF) domain score as measured by the EORTC QLQ-C30",
                    "description": "TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) final scores range from 0 to 100, where higher scores reflect better functioning",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "TDD for all participants in patient-reported PF domain score as measured by the EORTC QLQ-C30",
                    "description": "TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC QLQ-C30 final scores range from 0 to 100, where higher scores reflect better functioning.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "TDD for participants with IHC 3+ tumors in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain and Pruritis)",
                    "description": "TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC Quality of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer module (QLQ-BIL21) (Pain, Jaundice, Abdominal Pain, and Pruritis) final scores range from 0 to 100, where higher scores reflect better functioning.",
                    "timeFrame": "Up to 68 months"
                },
                {
                    "measure": "TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)",
                    "description": "TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis) final scores range from 0 to 100, where higher scores reflect better functioning.",
                    "timeFrame": "Up to 68 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC)..\n2. Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies.\n3. Received no more than 2 cycles of systemic therapy with gemcitabine and a platinum agent with or without a PD-1/L1 inhibitor (physician's choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectable or metastatic disease.\n4. HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and in situ Hybridization (ISH) assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy.\n5. Assessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), per investigator assessment.\n6. Male or female \u2265 18 years or age (or the legal age of adulthood per country-specific regulations).\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Adequate organ function\n9. Females of childbearing potential must have a negative pregnancy test result.\n10. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.\n\nExclusion Criteria\n\n1. Prior treatment with a HER2-targeted agent\n2. Prior treatment with checkpoint inhibitors, other than durvalumab or pembrolizumab\n3. The following BTC histologic subtypes are excluded: small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology, and mucinous cystic neoplasms detected in the biliary tract region.\n4. Use of systemic corticosteroids.\n5. Brain metastases\n6. Severe chronic or active infections\n7. History of allogeneic organ transplantation.\n8. Active or prior autoimmune inflammatory conditions\n9. History of interstitial lung disease or non-infectious pneumonitis.\n10. Participation in another clinical trial with an investigational medicinal product within the last 3 months.\n11. Females who are breastfeeding\n12. Any other medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Disclosure & Transparency",
                    "role": "CONTACT",
                    "phone": "215-832-3750",
                    "email": "ClinicalTrialDisclosure@JazzPharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Rocky Mountain Cancer Centers, LLP",
                    "status": "RECRUITING",
                    "city": "Lone Tree",
                    "state": "Colorado",
                    "zip": "80124",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.55171,
                        "lon": -104.8863
                    }
                },
                {
                    "facility": "Norton Cancer Institute - Audubon",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40217",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Minnesota Oncology Hematology, P.A.",
                    "status": "RECRUITING",
                    "city": "Maple Grove",
                    "state": "Minnesota",
                    "zip": "55369",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.07246,
                        "lon": -93.45579
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Centers",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10022",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Texas Oncology - DFW",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Hospital Oncologico, Puerto Rico Medical Center",
                    "status": "RECRUITING",
                    "city": "Rio Piedras",
                    "zip": "00935",
                    "country": "Puerto Rico",
                    "geoPoint": {
                        "lat": 18.39745,
                        "lon": -66.04989
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001661",
                    "term": "Biliary Tract Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M4947",
                    "name": "Biliary Tract Neoplasms",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T3096",
                    "name": "Intrahepatic Cholangiocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T761",
                    "name": "Biliary Tract Cancer",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2425",
                    "name": "Gallbladder Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "C000613593",
                    "term": "Durvalumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M272500",
                    "name": "Durvalumab",
                    "asFound": "Pancreatic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}